Literature DB >> 26454216

Interplay between menin and Dnmt1 reversibly regulates pancreatic cancer cell growth downstream of the Hedgehog signaling pathway.

Peng Cheng1, Yun-Feng Wang2, Gang Li1, Sheng-sheng Yang3, Che Liu1, Hao Hu1, Gang Jin4, Xian-Gui Hu1.   

Abstract

Menin, the product of the Men1 gene, which is frequently mutated in pancreatic neuroendocrine tumors, acts as a chromatin-remodeling factor to modulate the transcription of cell cycle regulators by interacting with histone modification factors. However, the function of menin and its underlying mechanisms in pancreatic ductal adenocarcinoma remain unknown. Here, we found that menin inhibited pancreatic cancer cell growth in vitro and in vivo and that its expression was gradually lost during pancreatic carcinogenesis. Menin overexpression significantly activated the expression of the cyclin-dependent kinase (CDK) inhibitors p18 and p27, accompanied with a decrease in DNA methylation levels of p18 and p27 promoters. Mechanistically, we found that interaction of menin with DNA methyltransferase 1 (Dnmt1) competitively pulled down Dnmt1 from p18 and p27 promoters, leading to the downregulation of DNA methylation levels. Moreover, menin expression was suppressed by Dnmt1 downstream of the Hedgehog signaling pathway, and menin overexpression strongly antagonized the promotion effect of hedgehog signaling on pancreatic cancer cell proliferation. Taken together, the interaction between menin and Dnmt1 reversibly regulates pancreatic cancer cell growth downstream of Hedgehog pathways with complex mutual modulation networks, suggesting that the Hedgehog/Dnmt1/menin axis is a potential molecular target for pancreatic cancer therapy.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dnmt1; Menin; Methylation; Pancreatic cancer cell growth; p18; p27

Mesh:

Substances:

Year:  2015        PMID: 26454216     DOI: 10.1016/j.canlet.2015.09.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  MAJOR MOLECULAR GENETIC DRIVERS IN SPORADIC PRIMARY HYPERPARATHYROIDISM.

Authors:  Andrew Arnold
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

Review 2.  A Review of the Scaffold Protein Menin and its Role in Hepatobiliary Pathology.

Authors:  Laurent Ehrlich; Chad Hall; Fanyin Meng; Terry Lairmore; Gianfranco Alpini; Shannon Glaser
Journal:  Gene Expr       Date:  2017-04-28

Review 3.  Epigenetic regulation by the menin pathway.

Authors:  Zijie Feng; Jian Ma; Xianxin Hua
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

Review 4.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

5.  The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms.

Authors:  Liping He; Steeve Boulant; Megan Stanifer; Cuncai Guo; Anna Nießen; Mingyi Chen; Klaus Felix; Frank Bergmann; Oliver Strobel; Simon Schimmack
Journal:  Cancer Sci       Date:  2022-03-08       Impact factor: 6.518

Review 6.  Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.

Authors:  Brittany R Silverman; Jiaqi Shi
Journal:  Int J Mol Sci       Date:  2016-12-19       Impact factor: 5.923

7.  The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1.

Authors:  Fang Zheng; JingJing Wu; Qing Tang; Qian Xiao; WanYin Wu; Swei Sunny Hann
Journal:  J Cell Mol Med       Date:  2017-08-25       Impact factor: 5.310

8.  Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.

Authors:  Longmei Li; JingJing Wu; Fang Zheng; Qing Tang; WanYin Wu; Swei Sunny Hann
Journal:  J Exp Clin Cancer Res       Date:  2016-07-16

9.  Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma.

Authors:  Hongzhe Li; Xinjing Wang; Yuan Fang; Zhen Huo; Xiongxiong Lu; Xi Zhan; Xiaxin Deng; Chenghong Peng; Baiyong Shen
Journal:  Oncotarget       Date:  2017-03-31

10.  Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a.

Authors:  Xiao Cui; Zhao Li; Jie Gao; Peng-Ji Gao; Yan-Bing Ni; Ji-Ye Zhu
Journal:  Oncotarget       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.